Positive results from a mid-stage study apparently weren’t enough to raise investor confidence in Praxis Precision Medicines ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

The White House set a 60-day deadline for drugmakers to agree on “most favored nation” prices for Medicaid as well as for ...

The 17 advisers fired last month by Robert F. Kennedy Jr. urged alternatives to ACIP be organized to limit further ...

A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place ...

Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results CEO Yvonne Greenstreet ...

Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...

Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA ...

The abrupt exit of the former CBER director raises questions about the FDA’s leadership. For now, newly appointed CDER head ...

The new direct-to-consumer ad signals J&J’s confidence in its capacity to meet demand for the cell therapy after earlier ...